Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and γ-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells

International Journal of Oncology

Volumn 33, Issue 4, 2008, Pages 851-859

  Hsieh, Tze Chen ^a   Wu, Joseph M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

tocotrienol; Epigallocatechin gallate; Phytochemical synergy; Resveratrol

Indexed keywords

CYCLIN D1; EPIGALLOCATECHIN GALLATE; ESTROGEN RECEPTOR; GAMMA TOCOTRIENOL; PLANT MEDICINAL PRODUCT; PROTEIN BCL 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RESVERATROL;

ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; CELL STRAIN MCF 7; COMBINATION CHEMOTHERAPY; COMBINATORIAL CHEMISTRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIETARY INTAKE; DRUG POTENTIATION; ENZYME INDUCTION; FEASIBILITY STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MONOTHERAPY; PHYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MODELS, BIOLOGICAL; STILBENES; SUPEROXIDE DISMUTASE; VITAMIN E;

EID: 54049115078     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000073     Document Type: Article

References (42)

1. Rock CL and Demark-Wahnefried W: Can lifestyle modification increase survival in women diagnosed with breast cancer? J Nutr 132: 3504S-3507S, 2002.
2. Rock E and DeMichele A: Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J Nutr 133: 3785S-3793S, 2003.
3. Taylor PR and Greenwald P: Nutritional interventions in cancer prevention. J Clin Oncol 23: 333-345, 2005.
4. Manson MM, Farmer PB, Gescher A and Steward WP: Innovative agents in cancer prevention. Recent Results Cancer Res 166: 257-275, 2005.
5. Paolini M, Abdel-Rahman SZ, Sapone A, Pedulli GF, Perocco P, Cantelli-Forti G and Legator MS: Beta-carotene: a cancer chemopreventive agent or a co-carcinogen? Mutat Res 543: 195-200, 2003.
6. Gescher AJ, Sharma RA and Steward WP: Cancer chemoprevention by dietary constituents: a tale of failure and promise. Lancet Oncol 2: 371-379, 2001.
7. Kline K, Yu W and Sanders BG: Vitamin E and breast cancer. J Nutr 134: 3458S-3462S, 2004.
8. Meyskens FL Jr and Szabo E: Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev 14: 1366-1369, 2005.
9. Liu RH: Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr 134: 3479S-3485S, 2004.
10. Pappa G, Strathmann J, Lowinger M, Bartsch H and Gerhauser C: Quantitative combination effects between sulforaphane and 3,3′-diindolylmethane on proliferation of human colon cancer cells in vitro. Carcinogenesis 28: 1471-1477, 2007.
11. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W and Yang CS: Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 63: 7563-7570, 2003.
12. Moyers SB and Kumar N-B: Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev 62: 204-211, 2004.
13. Simopoulos AP: The traditional diet of Greece and cancer. Eur J Cancer Prev 13: 219-230, 2004.
14. Aziz MH, Kumar R and Ahmad N: Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol 23: 17-28, 2003.
15. Schaffer S, Muller WE and Eckert GP: Tocotrienols: constitutional effects in aging and disease. J Nutr 135: 151-154, 2005.
16. Halliwell B, Rafter J and Jenner A: Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? Antioxidant or not? Am J Clin Nutr 81: 268S-276S, 2005.
17. Zingg JM and Azzi A: Non-antioxidant activities of vitamin E. Curr Med Chem 11: 1113-1133, 2004.
18. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC and Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997.
19. Pervaiz S: Resveratrol - from the bottle to the bedside? Leuk Lymphoma 40: 491-498, 2001.
20. Dong Z: Molecular mechanism of the chemopreventive effect of resveratrol. Mutat Res 523-524: 145-150, 2003.
21. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
22. Hebbar V, Shen G, Hu R, Kim BR, Chen C, Korytko PJ, Crowell JA, Levine BS and Kong AN: Toxicogenomics of resveratrol in rat liver. Life Sci 76: 2299-2314, 2005.
23. Jones SB, DePrimo SE, Whitfield ML and Brooks JD: Resveratrol-induced gene expression profiles in human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 14: 596-604, 2005.
24. Hsieh TC, Burfeind P, Laud K, Backer JM, Traganos F, Darzynkiewicz Z and Wu JM: Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. Int J Oncol 15: 245-252, 1999.
25. Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL and Wu JM: Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun 337: 224-231, 2005.
26. Hsieh TC and Wu JM: Differential control of growth, cell cycle progression, and gene expression in human estrogen receptor positive MCF-7 breast cancer cells by extracts derived from polysaccharopeptide I'm-Yunity and Danshen and their combination. Int J Oncol 29: 1215-1222, 2006.
27. Hsieh TC, Wu P, Park S and Wu JM: Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity (PSP). BMC Complement Altern Med 6: 30, 2006.
28. Aebi H: Catalase in vitro. Methods Enzymol 105: 121-126, 1984.
29. Lind C, Cadenas E, Hochstein P and Ernster L: DT-diaphorase: purification, properties, and function. Methods Enzymol 186: 287-301, 1990.
30. Stuart EC, Scandlyn MJ and Rosengren RJ: Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci 79: 2329-2336, 2006.
31. Kim YA, Choi BT, Lee YT, Park DI, Rhee SH, Park KY and Choi YH: Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol Rep 11: 441-446, 2004.
32. Srivastava JK and Gupta S: Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. Biochem Biophys Res Commun 346: 447-453, 2006.
33. Sugisawa A and Umegaki K: Physiological concentrations of (-)-epigallocatechin-3-O-gallate (EGCg) prevent chromosomal damage induced by reactive oxygen species in WIL2-NS cells. J Nutr 132: 1836-1839, 2002.
34. Yang CS, Chen L, Lee MJ, Balentine D, Kuo MC and Schantz SP: Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 7: 351-354, 1998.
35. Kim S, Lee MJ, Hong J, Li C, Smith TJ, Yang GY, Seril DN and Yang CS: Plasma and tissue levels of tea catechins in rats and mice during chronic consumption of green tea polyphenols. Nutr Cancer 37: 41-48, 2000.
36. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP and Brenner DE: Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16: 1246-1252, 2007.
37. Hong J, Lu H, Meng X, Ryu JH, Hara Y and Yang CS: Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res 62: 7241-7246, 2002.
38. Cuendet M, Oteham CP, Moon RC and Pezzuto JM: Quinone reductase induction as a biomarker for cancer chemoprevention. J Nat Prod 69: 460-463, 2006.
39. Belinsky M and Jaiswal AK: NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 12: 103-117, 1993.
40. Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T and Tsuruo T: DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res 56: 2823-2826, 1996.
41. Siegel D, Franklin WA and Ross D: Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 4: 2065-2070, 1998.
42. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D and Boothman DA: NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem 275: 5416-5424, 2000.